What is Sutro Biopharma's stock issuance proceeds?

Sutro Biopharma (STRO) reported stock issuance proceeds of $28K in Q1 2026.

What is the long-term trend for Sutro Biopharma's stock issuance proceeds?

Over 2 years (2021 to 2025), Sutro Biopharma's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $2.49M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Sutro Biopharma STRO Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Gilead SciencesGILD

$166M-34.1%

RegenxbioRGNX

$146K-2.7%

Nuvectis Pharma, Inc.NVCT

$3.95M+339%

XencorXNCR

$950K-68.1%

AnaptysBio, Inc.ANAB

$14.02M+4,735%

SchrodingerSDGR

$583K—

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's stock issuance proceeds?: Sutro Biopharma (STRO) reported stock issuance proceeds of $28K in Q1 2026.
What is the long-term trend for Sutro Biopharma's stock issuance proceeds?: Over 2 years (2021 to 2025), Sutro Biopharma's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $2.49M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.